Genentech's continued commitment to endocrinology
Genentech is a respected leader across a wide range of therapeutic areas. Our endocrinology research has led to several novel growth hormone products and innovative dosing regimens. In keeping with our commitment to health, Genentech continually monitors these products for their long-term safety and outcomes in patients. To date, Genentech-supported investigators have initiated over 200 studies and research projects, some of which have been presented at key endocrinology and nephrology meetings and published in journals.
Genentech also offers a variety of clinical resources to provide endocrinologists with assistance and data on growth disorders, GH deficiencies, and their treatment. Genentech is committed to the endocrinology community and the thousands of patients worldwide who live with growth hormone deficiency.
Genentech sponsors the following national studies to provide endocrinologists with important data on GH-related disorders and their treatment with GH therapy:
National Cooperative Metabolic Study (NCMS)—an observational database investigating adult growth hormone deficiency and its treatment
National Cooperative Growth Study (NCGS)—the largest observational database in the U.S. of children with growth disorders
Genentech also offers the following resources:
GT PLUS software, available to NCGS investigators only, allows efficient tracking of pediatric patients and electronic submission of data to the NCGS (National Cooperative Growth Study) database.
